Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.
|Abstract||To evaluate the clinical efficacy and safety of celecoxib combined with chemotherapy in the treatment of gastric cancer.|
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
|Publication Year Start||2018-01-01|
PMID- 29390421 OWN - NLM STAT- MEDLINE DCOM- 20180213 LR - 20180213 IS - 1536-5964 (Electronic) IS - 0025-7974 (Linking) VI - 96 IP - 51 DP - 2017 Dec TI - Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer. PG - e8857 LID - 10.1097/MD.0000000000008857 [doi] AB - BACKGROUND: To evaluate the clinical efficacy and safety of celecoxib combined with chemotherapy in the treatment of gastric cancer. METHODS: In total, 240 gastric cancer patients undergoing radical gastrectomy followed by adjuvant chemotherapy were randomly assigned into 2 groups. In the experimental group (n = 120), patients were administered with celecoxib-based chemotherapy, and chemotherapy alone was performed in the control group. Disease-free survival (DFS) and progression-free survival (PFS) were considered as the primary efficacy parameters, and objective response rate (ORR), overall survival (OS), quality of life (QOL), and safety as the secondary efficacy parameters. RESULTS: The 3-year OS did not significantly differ between the experimental (72%) and control groups (68%, P = .67). The 3-year DFS in the experimental group was 64%, which did not significantly differ from 51% in the control group (P = .41). In patients with positive cyclooxygenase-2 (COX-2) from the experimental group, the 3-year OS was 78%, significantly higher compared with 66% in the control group (P = .02), and the 3-year DFS was 70%, considerably >50% in the control group (P = .01). No statistical significance was identified in the incidence of nausea, neutropenia, anorexia, peripheral neurotoxicity, diarrhea, vomiting, asthenia, and thrombocytopenia, etc. The EORTC quality of life questionnaire (QLQ)-C30 questionnaire revealed that the global QOL in the experimental group was significantly higher than that in the control group (P < .05). No statistical significance was noted in the scores of functioning scale between 2 groups, whereas the scores of the symptom scale, especially pain and fatigue in the experimental group were remarkably higher than that in the control group (P < .05). The global score of EORTC QLQ-STO22 in the experimental group was considerably higher compared with that in the control group (P < .05). No statistical significance was identified in term of the domains of restrictions on feeding, dysphagia, anxiety, reflux, sense of taste, dry mouth, hair loss, and body shape between groups (all P > .05). CONCLUSION: Celecoxib combined with chemotherapy yields clinical benefits for gastric cancer patients with positive COX-2, which not only enhances the OS, DFS, PFS, QOL, and short-term clinical efficacy, but also does not increase the risk of adverse events. CI - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved. FAU - Guo, Qinghong AU - Guo Q AD - Department of Gastroenterology. FAU - Liu, Xiaojun AU - Liu X AD - Department of Oncology, the First Hospital of Lanzhou University, Lanzhou. FAU - Lu, Linzhi AU - Lu L AD - Department of Gastroenterology, Wuwei Tumor Hospital of Gansu Province, Wuwei, China. FAU - Yuan, Hao AU - Yuan H AD - Department of Gastroenterology. FAU - Wang, Yuping AU - Wang Y AD - Department of Gastroenterology. FAU - Chen, Zhaofeng AU - Chen Z AD - Department of Gastroenterology. FAU - Ji, Rui AU - Ji R AD - Department of Gastroenterology. FAU - Zhou, Yongning AU - Zhou Y AD - Department of Gastroenterology. LA - eng PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Cyclooxygenase 2 Inhibitors) RN - JCX84Q7J1L (Celecoxib) SB - AIM SB - IM MH - Adenocarcinoma/*drug therapy/mortality/pathology/psychology MH - Adolescent MH - Adult MH - Aged MH - Antineoplastic Combined Chemotherapy Protocols MH - Celecoxib/administration & dosage/*therapeutic use MH - Chemotherapy, Adjuvant MH - China MH - Cyclooxygenase 2 Inhibitors/administration & dosage/*therapeutic use MH - Disease-Free Survival MH - Female MH - Gastrectomy MH - Humans MH - Male MH - Middle Aged MH - *Quality of Life MH - Stomach Neoplasms/*drug therapy/mortality/pathology/psychology MH - Treatment Outcome MH - Young Adult PMC - PMC5758123 EDAT- 2018/02/03 06:00 MHDA- 2018/02/14 06:00 CRDT- 2018/02/03 06:00 PHST- 2018/02/03 06:00 [entrez] PHST- 2018/02/03 06:00 [pubmed] PHST- 2018/02/14 06:00 [medline] AID - 10.1097/MD.0000000000008857 [doi] AID - 00005792-201712220-00008 [pii] PST - ppublish SO - Medicine (Baltimore). 2017 Dec;96(51):e8857. doi: 10.1097/MD.0000000000008857.